Synergy Pharmaceuticals, Inc. (SGYP) financial statements (2021 and earlier)

Company profile

Business Address 420 LEXINGTON AVENUE
NEW YORK, NY 10170
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments137821121966833
Cash and cash equivalents13782621461812
Short-term investments  50505020
Receivables6     
Inventory, net of allowances, customer advances and progress billings176  
Inventory176    
Prepaid expense and other current assets2
Other undisclosed current assets41344 
Total current assets:165891152007234
Noncurrent Assets
Property, plant and equipment111110
Long-term investments and receivables     3
Due from related parties     3
Deferred costs   12  
Other undisclosed noncurrent assets000000
Total noncurrent assets:1111313
TOTAL ASSETS:167901162137337
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities38292018167
Accounts payable23161314145
Accrued liabilities15144222
Interest and dividends payable0023  
Total current liabilities:38292018167
Noncurrent Liabilities
Long-term debt and lease obligation9923151200  
Long-term debt, excluding current maturities9923151200  
Liabilities, other than long-term debt1800025
Other liabilities0     
Derivative instruments and hedges, liabilities1800025
Other undisclosed noncurrent liabilities17     
Total noncurrent liabilities:1342315220025
Total liabilities:172521712191713
Stockholders' equity
Stockholders' equity attributable to parent(6)38(55)(5)5525
Common stock000000
Additional paid in capital802621329262227134
Accumulated deficit(807)(583)(384)(267)(171)(109)
Total stockholders' equity:(6)38(55)(5)5525
TOTAL LIABILITIES AND EQUITY:167901162137337

Income statement (P&L) ($ in millions)

12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Revenues17     
Cost of revenue(9)     
Gross profit:8     
Operating expenses(230)(145)(100)(94)(62)(38)
Other undisclosed operating income     0
Operating loss:(222)(145)(100)(94)(62)(38)
Nonoperating income (expense)(2)(53)(18)(1)0(1)
Investment income, nonoperating   (2)00
Other nonoperating income 0 0 1
Interest and debt expense(1)(7)(5)(3)(0) 
Net loss attributable to parent:(226)(206)(122)(99)(62)(39)
Other undisclosed net income available to common stockholders, basic17530 
Net loss available to common stockholders, diluted:(224)(199)(118)(96)(62)(39)

Comprehensive Income ($ in millions)

12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Net loss:(226)(206)(122)(99)(62)(39)
Comprehensive loss, net of tax, attributable to parent:(226)(206)(122)(99)(62)(39)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: